Allay Therapeutics
San Jose
About Allay Therapeutics
Allay is pioneering a new category of ultra-sustained pain therapeutics to transform post-surgical pain management and recuperation for patients and physicians. Allay’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable therapeutics to deliver pain relief within a targeted site over weeks’an order of magnitude greater than the longest-lasting pain treatments currently available. The company’s lead investigational product candidate, ATX101, is currently being evaluated in a Phase 2 clinical study in TKA surgeries. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $149.5M
- Funding stage: Late Stage Venture
- Last round: Series D (Jun 2025)
- Website: allaytx.com
- Phone: +1 617-834-0936
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/allay-therapeutics-30827 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.